[Erlotnib in the treatment of advanced non-small cell lung cancer failed to previous chemotherapy].
OBJECTIVE
To investigate the efficacy and side effect of erlotnib for refractory patients with advanced non-small cell lung cancer (NSCLC) failed to previous chemotherapy.


METHODS
Twelve patients with chemo-refractory NSCLC were enrolled into this study. Erlotnib was administered at a dose of 150 mg orally once a day for a month. The assessment was carried out every month by intensive clinical observation and monthly CT scan until disease progression or intolerable toxicity occurred.


RESULTS
All the 12 patients were evaluable. The response rate including complete and partial responses (CR and PR) was 25.0% (3/12). The disease control rate including complete, partial response and stable disease (CR, PR and NC) was 58.3% (7/12). The clinical benefit rate was 41.7% (5/12). The main side effects included skin rash and diarrhea. No patient was withdrawn from the treatment due to intolerable toxicities.


CONCLUSIONS
Erlotnib is effective and tolerable in the treatment of patients with advanced NSCLC failed to previous chemotherapy.
Zhang
Feng
F
Department of Radiation Oncology, The Second Affiliated Hospital, Harbin Medical University, Harbin 150086, China.
Xing
Li-na
LN
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002272:Carcinoembryonic Antigen / Q000097:blood; D002289:Carcinoma, Non-Small-Cell Lung / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D002945:Cisplatin / Q000008:administration & dosage; D003967:Diarrhea / Q000139:chemically induced; D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D000069347:Erlotinib Hydrochloride; D005076:Exanthema / Q000139:chemically induced; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D047428:Protein Kinase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D011788:Quality of Life; D011799:Quinazolines / Q000009:adverse effects / Q000627:therapeutic use*; D012074:Remission Induction; D017211:Treatment Failure; D055815:Young Adult
D002272:Carcinoembryonic Antigen; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D000069347:Erlotinib Hydrochloride; D066246:ErbB Receptors; D002945:Cisplatin